Cargando…
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIR...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259379/ https://www.ncbi.nlm.nih.gov/pubmed/30226089 http://dx.doi.org/10.1177/0300060518799612 |
_version_ | 1783374665008283648 |
---|---|
author | Zhang, Jin Jin, Shenhe Guo, Xiaojun Qian, Wenbin |
author_facet | Zhang, Jin Jin, Shenhe Guo, Xiaojun Qian, Wenbin |
author_sort | Zhang, Jin |
collection | PubMed |
description | The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma. |
format | Online Article Text |
id | pubmed-6259379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62593792018-11-30 Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy Zhang, Jin Jin, Shenhe Guo, Xiaojun Qian, Wenbin J Int Med Res Reviews The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma. SAGE Publications 2018-09-18 2018-11 /pmc/articles/PMC6259379/ /pubmed/30226089 http://dx.doi.org/10.1177/0300060518799612 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Reviews Zhang, Jin Jin, Shenhe Guo, Xiaojun Qian, Wenbin Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title | Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title_full | Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title_fullStr | Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title_full_unstemmed | Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title_short | Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy |
title_sort | targeting the cd47-sirpα signaling axis: current studies on b-cell lymphoma immunotherapy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259379/ https://www.ncbi.nlm.nih.gov/pubmed/30226089 http://dx.doi.org/10.1177/0300060518799612 |
work_keys_str_mv | AT zhangjin targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy AT jinshenhe targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy AT guoxiaojun targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy AT qianwenbin targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy |